Explainer: What is Unitree and why are China's humanoid robot makers racing to list?

• Unitree's revenue grew more than fourfold to nearly 1.7 billion yuan in 2025, with over 40% coming from overseas sales, making it profitable unlike many humanoid startups
• Current demand mostly comes from universities and government-backed projects rather than commercial applications, as humanoids still struggle with reliability and performing varied tasks without human intervention
• Multiple Chinese robotics companies are rushing to go public, including Leju Robotics (filed for Shenzhen listing in May) and AgiBot (began Hong Kong IPO preparations in July), seeking capital for heavy R&D spending before mass-market demand materializes

Summary: Unitree's Shanghai IPO and China's Humanoid Robot Race

Key Development:

Chinese robotics manufacturer Unitree is set to become the first mainland-listed humanoid robot maker, pricing its Shanghai IPO at 150.8 yuan per share to raise over $900 million.

Company Background:

Founded in 2016 by engineer Wang Xingxing, Hangzhou-based Unitree initially gained recognition for affordable quadruped robots (robot dogs). The company now competes with Tesla and Boston Dynamics through its G1, H1, and R1 humanoid models, which have achieved viral attention demonstrating running, dancing, and martial arts capabilities.

Financial Performance:

• Revenue surged over 400% to nearly 1.7 billion yuan in 2025
• Adjusted net profit reached approximately 600 million yuan
• Unlike most humanoid startups, Unitree is profitable
• International sales exceed 40% of total revenue

Market Significance:

Unitree exemplifies China's ability to manufacture sophisticated robots at significantly lower prices than Western competitors, leveraging extensive domestic supply chains for motors, sensors, and batteries. The company symbolizes Beijing's ambition to dominate "embodied intelligence"—integrating AI with physical machines.

Industry Challenges:

Current demand primarily comes from universities and government projects for education and research rather than commercial applications. Humanoids still face limitations in reliability, dexterity, and sustained autonomous operation.

Broader Trend:

Other Chinese robotics companies are pursuing public listings to fund intensive R&D requirements. Leju Robotics filed for Shenzhen's ChiNext listing in May, while AgiBot began Hong Kong IPO preparations in July. These listings aim to secure capital during peak government support and investor enthusiasm, despite uncertain long-term commercial viability.